从兰州街头摊贩叫卖的泰国金枕榴莲，到马来西亚市场热销的甘肃礼县柑橘，中国西北内陆省份甘肃与 东盟国家在农产品贸易、中医药、文旅等多个领域碰撞出火花。 6日至10日，第31届中国兰州投资贸易洽谈会举办。在主宾国印尼展销区，手工艺品和咖啡畅销；泰国 展区的清凉油、青草药，柬埔寨的风味虾片，受到消费者追捧…… "我们根据双方消费习惯挑选适销商品，甘肃苹果、高原夏菜、中药材在东盟很有潜力。"甘肃驻马来西 亚商务代表处首席代表马玉田9日接受中新社记者采访时说，通过"甘香丝路，食联南洋"等推介会，已 有多项农贸协议落地，"环球撮合荟"马来西亚国别馆更成为甘肃农产品的海外展示窗口。 在泰国，甘肃驻泰国商务代表处首席代表虎炎正推动中医药文化落地生根。据她介绍，首批21名泰国学 员已毕业，甘肃中医药大学(曼谷)敦煌医学科在泰国设立，两位甘肃中医专家即将赴泰开展临床教学， 让针灸等中医疗法惠及更多当地民众。 柬埔寨甘肃商会会长火照国则忙着为家乡特产"牵线"。"甘肃的洋葱、宽粉、中草药在东南亚很受欢 迎，莫高窟与吴哥窟的文旅对接也大有可为。"他说，希望推动双方在农业、文旅领域深度合作。 另悉，2024年甘肃入境游客同比增长137% ...

Core Insights - The emergence of traditional Chinese medicine (TCM) night markets in Xinxiang has integrated TCM services into local community life, enhancing public awareness of TCM culture [1][2][3] Group 1: TCM Night Market Activities - The TCM night market in Huojia County features four main components: expert consultations, therapy experiences, intangible cultural heritage displays, and food and medicine tasting, attracting long queues of visitors [1] - In Weihu City, the "Health Night Market" offers traditional TCM therapy experiences and herbal soups, which are particularly popular among children and the elderly [2] - Fengquan District's "Midsummer Night Health" event combines TCM and Western medicine services, creating a comprehensive health service system that includes medication guidance and lifestyle interventions [2] Group 2: Community Engagement and Economic Impact - The TCM night market has become a new social landmark for residents, fostering community interactions and increasing health awareness from disease treatment to prevention [3] - The presence of TCM night markets has significantly boosted local economies, with surrounding food stalls and creative shops experiencing daily revenue increases of over 60% due to the influx of visitors [2]

□ 本报记者程晓琳蒋明睿 宁波卫生职业技术学院朱晓卓教授认为，通过适老化改造与中医体质辨识结合，有助于降低社区老年人 的跌倒发生率，"这证明中医药完全可以融入居家养老的全链条。"华东政法大学苏玉菊教授则从全球视 野发现，构建以人为本的整合型医疗卫生服务体系已成为全球医疗卫生改革的重要方向，需通过法律推 动医疗、养老、护理资源"从碎片化到系统化"。"南京中医药大学团队正在制定南京市老年人陪同就医 服务规范，有望缓解目前陪同就医人员不足、缺乏准入标准、服务不规范等问题。"喻小勇补充。 "中国90%以上的老人选择居家养老。但最主要的短板，是基层专业服务体系网络的托底问题！"7月5 日，在南京中医药大学召开的全国中医药法治研究联盟2025年学术年会上，南京中医药大学养老服务与 管理研究院常务副院长田侃教授的声音里透着紧迫。在不少一二线城市，完善的社区老年康养服务仍属 稀缺品。老人渴望"安居家中"，却难以就近获得中医药便捷有序的专业医疗支持。 值得关注的是，澳大利亚全国中医药针灸学会联合会会长林子强分享的"40年立法路"引发深思。他认 为，应通过立法实现中医与西医法律地位平等，为全球提供镜鉴。"中国的挑战更为复杂，但优 ...

7月6日，2025（第42 届）全国医药工业信息年会上，好医生集团"诠释中药科学内涵 推动新药研发"项目从全国医药企业中脱颖而出，荣获"2025 年中国医 药工业企业社会责任优秀案例"，39年守正创新发展中医药的责任感和使命感获得高度认可。 这些成果背后是强大的知识产权支撑，好医生集团现拥有注册商标2000多件，好医生集团已累计获得 460 项国家授权专利，6个原始一类新药均拥有国际 PCT 专利，承担 70 余项国家级科研课题。先后荣获国家专利奖、中华中医药学会科技进步一等奖、科技部华夏科技奖一等奖、四川省科技进步一等奖、四 川省专利二等奖等科研创新荣誉。 带着强烈的社会责任感，在科研创新的同时，好医生集团始终践行着"关爱大众健康"的使命。近年来，集团联合编制出版了美洲大蠊和康复新液系列丛书， 让更多人可以深入了解美洲大蠊的药用功效。该系列丛书由《中药美洲大蠊大全》《康复新液临床研究与应用》《康复新液临床研究与应用（普及版）》 《药用美洲大蠊基因组学研究》《药用美洲大蠊基因成分研究》等组成。尤其是《康复新液临床研究与应用（普及版）》一书，将专业的医学理论转化为通 俗易懂的科普内容，有效打破了医学知识的壁垒， ...

Group 1 - The article emphasizes the limitations of AI in the medical field, particularly in capturing the nuances of human emotions and individual differences, highlighting the value of traditional Chinese medicine (TCM) in addressing these gaps [1] - TCM's holistic approach, focusing on concepts like "Qi," "Yin-Yang," and "meridians," is presented as a complementary solution to modern medical practices, especially in the area of preventive care [1] - The company, Kangchi Health Industry Group, is committed to the inheritance and modernization of TCM, aiming to enhance cultural confidence and national identity through a multi-dimensional TCM ecosystem [1] Group 2 - Data shows that the configuration rate of AI-assisted tongue and pulse diagnosis devices in TCM clinics has reached 73%, promoting standardization in grassroots TCM practices [2] - The Kangchi Yisheng APP, developed by Kangchi Group, integrates AI with TCM diagnostics, allowing for rapid and accurate health assessments based on tongue images, thus providing objective diagnostic support for practitioners [2] - The APP also compiles a vast knowledge graph of TCM clinical cases, enabling AI-assisted systems to offer diverse diagnostic and treatment options, significantly improving efficiency and accuracy in patient care [2] Group 3 - In the AI era, the health sector is calling for diverse and integrated solutions, with Kangchi Group leveraging technology to preserve TCM heritage and drive its development [3] - The company is focused on creating a comprehensive ecosystem that encompasses smart diagnostics, educational innovations, and the management of the entire TCM industry chain [3] - Kangchi Group aims to ensure that every health decision made in the AI era is informed by a profound understanding of life, ensuring the continuity of TCM wisdom [3]

Core Viewpoint - The integration of traditional Chinese medicine culture with modern night market economy is creating unique experiences for citizens, enhancing cultural tourism during the summer season [1][2]. Group 1: Event Overview - The third "Da Song Traditional Chinese Medicine Culture Market" was held in Kaifeng, allowing citizens to experience various traditional Chinese medicine practices and receive expert medical consultations [1]. - The event aims to promote traditional Chinese medicine culture and enrich the summer cultural tourism market, focusing on "inheritance, experience, and health" [1]. Group 2: Government Initiatives - In January 2023, the State Council issued measures to cultivate new growth points and promote cultural and tourism consumption, emphasizing the development of night economy [1]. - Various regions are exploring diverse night economy formats, including traditional Chinese medicine night markets, to invigorate local economies [1]. Group 3: Regional Developments - Other provinces such as Shandong, Liaoning, and Sichuan have also hosted traditional Chinese medicine night markets, featuring activities like medicinal cuisine preparation and acupuncture workshops to attract younger audiences [1].

Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange (HKEX) saw 11 companies submit applications for listing from June 30 to July 6, with no companies passing the listing hearing during this period. Additionally, 7 companies initiated their public offerings, and 5 new stocks were listed. Group 1: Companies Submitting Applications - Puxiang Health Holdings Limited is a leading provider of integrated medical and elderly care services in North China, ranking second in revenue among its peers and first in revenue growth from 2022 to 2024 [2] - Magnesium Health Technology Co., Ltd. focuses on innovative payment solutions for medical expenses, being the largest provider of innovative health insurance solutions in China by policy count [3] - Yangtuo Technology Inc. operates a trading and service platform for home care and nutrition products, holding a 10.1% market share in the low-tier market [4] - Xiamen Ruiwei Information Technology Co., Ltd. specializes in image intelligent analysis products and solutions, leveraging machine learning and computer vision technologies [5] - Zijin Gold International Limited is a leading global gold mining company, ranking ninth in gold reserves and eleventh in production as of 2024 [6] - EVE Energy Co., Ltd. is a leading lithium battery platform company, ranking first in China for consumer cylindrical battery shipments and second globally for energy storage battery shipments [7] - Zhejiang Yifei Intelligent Technology Co., Ltd. is a leading industrial robotics company in China, focusing on the light industry [8] - ChipMight Semiconductor Technology (Hangzhou) Co., Ltd. is a leading power semiconductor company, ranking second in the global OLED display PMIC market [9] - Beijing Tongrentang Medical Investment Co., Ltd. is the largest non-public Chinese medicine hospital group by outpatient and inpatient visits [11] - Shandong Linglong Tire Co., Ltd. is the largest OE tire manufacturer in China and the third largest globally [12] - Magnesium Holdings Limited is an innovative automotive technology company focused on AI-driven integrated domain control solutions [13] Group 2: Public Offerings and New Listings - Seven companies initiated their public offerings, including Anjii Foods, which had a subscription rate of 44.2 times for its public offering [14][15] - Other companies like Lens Technology and Fortior also initiated their public offerings with significant interest from cornerstone investors [16][19] - Five new stocks were listed, including Yunzhisheng, which saw a closing price increase of 44.59% on its first day [20][21][22][23] Group 3: Market Insights - The Hong Kong Stock Exchange raised over HKD 107 billion in the first half of 2025, with a 20% increase in the Hang Seng Index [24] - The biopharmaceutical sector has seen a resurgence, with 10 companies successfully listing in the first half of 2025, compared to only 12 for the entire previous year [25][26] - The total fundraising amount for the biopharmaceutical sector reached HKD 15.6 billion in the first half of 2025, indicating strong market interest [26][27]

Core Viewpoint - The company, Panlong Pharmaceutical, has transformed from a near-bankrupt small factory into a nearly 10 billion yuan traditional Chinese medicine listed enterprise over 27 years, focusing on high-quality development and a comprehensive health strategy [1] Group 1: Corporate Governance and Development Strategy - The company integrates party building into its governance structure, with all board members being party committee members, ensuring that the party organization has real power in strategic decision-making [2] - The unique "12345" party building model has led to significant operational improvements, including a 40% efficiency increase in tablet production lines and over 10 million yuan in annual cost savings [2] - The company has achieved a 45.28% growth in main business revenue and a 47.89% increase in net profit over the past five years, with R&D investment consistently exceeding 6% [2] Group 2: Product and Market Development - In 2024, the company's self-produced traditional Chinese medicine generated revenue of 645 million yuan, a year-on-year increase of 10.20%, with its revenue share rising from 59.67% to 66.22% [4] - The company aims to become a leading player in the Chinese herbal formula granules market, targeting over 400 products for production and sales [4] Group 3: Social Responsibility and Community Engagement - The company has implemented a "Five Guarantees Poverty Alleviation Model," resulting in an average annual income increase of 24,000 yuan for 7,520 households [5][6] - Panlong Pharmaceutical has established a 100 million yuan charitable fund and has been recognized as a national green factory, contributing to local economic development and social welfare [6] Group 4: Future Outlook - The company plans to deepen its "one body, two wings, three depths" development strategy by focusing on orthopedic chronic diseases and enhancing its product matrix across various therapeutic areas by 2025 [7]

Group 1 - A media team from Kazakhstan experienced traditional Chinese medicine at the Dongfang International Traditional Chinese Medicine Culture and Health Center in the Horgos International Border Cooperation Center [1][3] - The team members reported significant relief from chronic pain and discomfort after receiving treatments such as massage, cupping, and pulse diagnosis [1][3] - The center has seen an increase in Kazakh patients suffering from chronic conditions like leg pain, back pain, hypertension, and arthritis [3] Group 2 - The effectiveness of traditional Chinese medicine was highlighted through personal testimonials from Kazakh media professionals who experienced immediate benefits from the treatments [1][3] - The treatments provided at the center are tailored to address specific health issues, demonstrating the precision and adaptability of traditional Chinese medical practices [1][3] - The positive experiences of the media team may lead to increased interest and potential future visits from other Kazakh patients seeking similar treatments [1][3]

来源：健业家 | | | | 2025年医疗健康IP0统计 | | | | --- | --- | --- | --- | --- | --- | | 企业 | 行业 | 上市状态 | 在北 | 行业 | 上市状态 | | 劲方医药 | 创新药 | 港股域表 | 阿正中医 | 中医 | 港股进表 | | 先通医药 | 创新药 | 港股越表 | 同仁堂医养 | 中医 | 港股进表 | | 迈威生物 | 创新药 | 港股邊表 | 新荷花中药饮片 | 中医 | 港股进表 | | 百利天恒 | 创新药 | 港股速表 | 微医 | 互联网医疗 | 港股进表 | | 宝济药业 | 创新药 | 港股域表 | 微脉 | 互联网医疗 | 港股进表 | | 科望医药 | 创新药 | 港股递表 | 健康160 | 互联网医疗 | 港股进表 | | 景泽生物 | 创新药 | 港股递表 | 轻松健康 | 保险 | 港股进表 | | 旺山旺水生物 | 创新药 | 港股遗表 | 镁信健康 | 保障 | 港股通表 | | 真实生物 | 创新药 | 港股越表 | 大医集团 | 医疗器械 | 港股进表 | | 亦诺微 | 创新药 | 港股递表 ...